Developmental & Aging Neuroscience

← Back to Neuroscience

Brain development, aging, neurodegeneration, and lifespan neuroscience.

The human brain undergoes continuous remodeling across the lifespan, from the highly plastic stages of early development to the complex biological shifts of advanced age. Understanding this trajectory requires examining the precise molecular, structural, and vascular mechanisms that govern both healthy cognitive function and neurodegenerative decline.

Early neural development relies on critical periods of synaptic pruning and myelination, which shape cognitive and emotional architectures. While early life adversity can disrupt these pathways, the adult brain retains a capacity for remodeling. Researchers continue to map the boundaries of adult neuroplasticity and the ongoing debate surrounding adult neurogenesis, exploring how targeted habits can overcome molecular brakes to facilitate cognitive adaptability. This cognitive evolution shifts over time, transitioning from the fluid intelligence of youth to crystallized creative wisdom in later years.

As the brain ages, physiological changes—including synaptic degradation, epigenetic shifts, and altered time perception driven by metabolic and hippocampal changes—mark the transition into later life. A central focus of healthy aging research is waste clearance. The glymphatic system, active during sleep, relies on arterial pulsatility and specialized channels to remove toxic proteins. When these clearance systems fail, or when the blood-brain barrier suffers vascular breakdown, cellular senescence and systemic inflammation can trigger microglial activation, leading to neurodegenerative pathologies.

In the clinical arena, the differentiation between normal cognitive aging and diseases like Alzheimer’s and Parkinson’s is becoming increasingly precise. This includes identifying lifestyle and pharmacological risks, such as the link between chronic diphenhydramine use and dementia. Diagnostic capabilities are expanding with FDA-cleared blood tests, such as p-tau217 assays, improving early detection. Therapeutic pipelines are also accelerating, particularly through novel tau-targeting strategies, including genetic silencing and monoclonal antibodies, alongside critical regulatory updates on subcutaneous drug delivery. Together, these insights illuminate the biological determinants of brain health and the emerging tools poised to preserve it.

21 published articles